Entering text into the input field will update the search result below

Soliris an Orphan Drug in Japan for neuromyelitis optica

Nov. 25, 2014 7:25 AM ETAlexion Pharmaceuticals, Inc. (ALXN) StockBy: Douglas W. House, SA News Editor
  • The Japanese Ministry of Health, Labour and Welfare grants Orphan Drug status to Alexion Pharmaceuticals' (NASDAQ:ALXN) Soliris (eculizumab) for the treatment of patents with neuromyelitis optica, a life-threatening ultra-rare neurologic disorder.
  • The Japanese regulator grants Orphan Drug status to medicines that treat diseases afflicting less than 50K people in Japan. Among the benefits is a 10-year period of market exclusivity if approved.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
ALXN--
Alexion Pharmaceuticals, Inc.